Drug Profile
Miridesap - GlaxoSmithKline
Alternative Names: CPHPC - GlaxoSmithKline; GSK2315698; GSK2315698ALatest Information Update: 28 May 2021
Price :
$50
*
At a glance
- Originator Pentraxin Therapeutics
- Developer GSK
- Class Antidementias; Pyrrolidines
- Mechanism of Action Serum amyloid P component inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Amyloidosis
Most Recent Events
- 28 May 2021 No recent reports of development identified for phase-I development in Amyloidosis(Combination therapy) in Sweden (IV, Infusion)
- 28 Dec 2019 No recent reports of development identified for phase-I development in Amyloidosis(In volunteers) in Japan (IV, Infusion)
- 16 Oct 2019 GlaxoSmithKline terminates a phase II trial in Amyloidosis in USA and United Kingdom (NCT03044353)